Skip to main content

Table 1 Clinical characteristics of samples used in this study

From: Genetic and functional association of FAM5C with myocardial infarction

Variable

eoCAD Probands

ACS Probands

MI Cases

Controls

Aorta Samples

 

(n = 422)

(n = 228)

(n = 368)

(n = 289)

(n = 88)

Age of onset (SD)

44.2 (5.8)

43.9 (6.1)†

51.5 (10.2)†

69.0 (7.0) exam

37.8 (13.2)

Race: Caucasian

92.9%

93%†

100%†

100.0%

87.9%

African American

2.1%

2.2%

0.0%

0.0%

8.6%

American Indian

4.0%

3.0%

0.0%

0.0%

0.0%

Asian

0.7%

0.9%

0.0%

0.0%

2.0%

Hispanic

0.0%

0.0%

0.0%

0.0%

3.5%

Other (unknown)

0.2%

0.4%

0.0%

0.0%

0.0%

Sex: Male

70.6%

72%†

83%†

43.0%

55.2%

Family history of CAD

100.0%

100%†

58%†

28.0%

 

Body Mass Index (SD)

29.9 (5.8)

29.9 (6.3)

29.9 (6.8)

28.2 (6.5)

 

Smoking

78.0%

84.0%†

72%†

39.0%

 

Diabetes

22.3%

22.0%

29.0%

15.0%

 

Hypertension

56.9%

57%†

66%†

66.0%

 

MI

65.9%*

89.0%*†

100%†

0.0%

Data not available

Sys/Dias BP (SD)

140.1/84.0* (21.5/11.4)

140.6†/87.0* (22.0/12.0)

138.0†/74.0 (24.0/12.0)

149.0/76.0 (23.0/13.0)

 

Total Cholesterol (SD)

239.1 (64.8)

235.0† (67.0)

189.0† (56.0)

189.0 (43.0)

 

LDL (SD)

146.1 (54.3)

161.0† (125.0)

108† (42.0)

105.0 (35.0)

 

HDL (SD)

38.67 (16.3)

40.0 (14.0)

39.0 (12.0)

51.0 (19.0)

 

Triglycerides (SD)

230.1 (138.8)

221.0 (157.0)

226.0 (239.0)

169.0 (133.0)

 
  1. *significant difference between eoCAD and ACS probands (p ≤ 0.05)
  2. †significant difference between ACS probands and MI cases (p ≤ 0.05)